1. Search Result
Search Result
Results for "

covalently

" in MedChemExpress (MCE) Product Catalog:

527

Inhibitors & Agonists

6

Screening Libraries

55

Fluorescent Dye

6

Biochemical Assay Reagents

13

Peptides

4

MCE Kits

2

Inhibitory Antibodies

13

Natural
Products

12

Isotope-Labeled Compounds

27

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-163267

    Others Others
    ZNL0325 is a covalent probe based on pyrazolopyrimidine. ZNL0325 features an acrylamide side chain at the C3 position, which is capable of forming covalent bonds with multiple kinases that possess a cysteine at the αD-1 position, including BTK, EGFR, BLK, and JAK3. ZNL0325 can be used in the research of creating structurally distinct covalent kinase inhibitors .
    ZNL0325
  • HY-154975

    SARS-CoV Others
    SARS-CoV-2-IN-49 is an irreversible covalent inhibitor of SARS-CoV-2 main protease .
    SARS-CoV-2-IN-49
  • HY-E70211

    HaeIII

    DNA Methyltransferase Cancer
    HaeIII Methyltransferase (HaeIII) is a Methyltransferase which can bind covalently to DNA .
    HaeIII Methyltransferase
  • HY-155979

    SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-16 (Compound 3a) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 2.124 μM). SARS-CoV-2 3CLpro-IN-16 binds to the active site and forms a covalent bond with Cys145 of 3CLpro .
    SARS-CoV-2 3CLpro-IN-16
  • HY-126152

    Others Others
    Chlorthiamid is a broad-spectrum herbicide. Chlorthiamid is an olfactory toxicant with a high in vivo covalent binding in the olfactory mucosa of mice .
    Chlorthiamid
  • HY-155187

    SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-20 (Compound 5g) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 0.43 μM, Ki: ?0.33?μM) .
    SARS-CoV-2 3CLpro-IN-20
  • HY-148535

    Proteasome Neurological Disease
    Calpain Inhibitor XI is a reversible covalent inhibitor of calpain-1. Calpain Inhibitor XI can be used for the research of neurodegenerative disorders .
    Calpain Inhibitor XI
  • HY-132196

    Btk Inflammation/Immunology
    BTK inhibitor 18 is a potent, selective,orally active and covalent Btk inhibitor with a IC50 of 142 nM. BTK inhibitor 18 has anti-inflammatory activities .
    BTK inhibitor 18
  • HY-136605
    DGY-06-116
    1 Publications Verification

    Src Cancer
    DGY-06-116 is an irreversible covalent, selective Src inhibitor with an IC50 of 3nM. DGY-06-116 inhibits FGFR1 with an IC50 of 8340 nM .
    DGY-06-116
  • HY-U00279

    DNA/RNA Synthesis Cancer
    Nitracrine inhibits RNA synthesis and covalently, reversibly binds to DNA but also forms covalent adducts with DNA in vivo. Nitracrine, a 1-nitroacridine derivative, is a potent hypoxia-selective agent in vitro and antitumor agent. Nitracrine has cytotoxicity towards most cells .
    Nitracrine
  • HY-U00279A

    DNA/RNA Synthesis Cancer
    Nitracrine (dihydrochloride hydrate) inhibits RNA synthesis and covalently, reversibly binds to DNA but also forms covalent adducts with DNA in vivo. Nitracrine (dihydrochloride hydrate), a 1-nitroacridine derivative, is a potent hypoxia-selective agent in vitro and antitumor agent. Nitracrine (dihydrochloride hydrate) has cytotoxicity towards most cells .
    Nitracrine dihydrochloride hydrate
  • HY-143474

    Prolyl Endopeptidase (PREP) Neurological Disease Cancer
    Y-29794 (Compound 2) is a potent, covalent prolyl oligopeptidase (POP) inhibitor with a Ki of 0.95 nM. Y-29794 can be used for studying neurodegenerative diseases and cancer .
    POP-IN-3
  • HY-143475

    Prolyl Endopeptidase (PREP) Neurological Disease Cancer
    POP-IN-2 (Compound 7k) is a potent, covalent prolyl oligopeptidase (POP) inhibitor with a Ki of 6 nM. POP-IN-2 can be used for studying neurodegenerative diseases and cancer .
    POP-IN-2
  • HY-132234

    Epigenetic Reader Domain Cancer
    M‑1121 is a covalent and orally active inhibitor of the menin-MLL interaction capable of achieving complete and persistent tumor regression .
    M-1211
  • HY-143902

    PIN1 Cancer
    ZL-Pin01 is a high potent covalent Pin1 (Peptidyl-Prolyl Isomerase NIMA-Interacting-1) inhibitor. ZL-Pin01 shows potent disruption of the Pin1-substrate interaction with an IC50 of 1.33 μM .
    ZL-Pin01
  • HY-155772

    Adenosine Receptor Fluorescent Dye Inflammation/Immunology
    LUF7690 (Compound 9) is a clickable and covalent affinity-based probe (AfBP) that targets the human A3AR (hA3AR). LUF7690 can be used in the detection and characterization of the hA3AR in different types of granulocytes, among other cell types .
    LUF7690
  • HY-117430

    F-244; 1233A; L-659699

    Flavivirus Dengue virus Antibiotic Infection Metabolic Disease Cancer
    Hymeglusin, as a fungal β-lactone antibiotic, is a HMG-CoA synthase inhibitor (IC50 = 0.12 μM). Hymeglusin covalently modifies the active Cys 129 residue of the enzyme .
    Hymeglusin
  • HY-157778

    SARS-CoV Infection
    MK-7845 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC50 of 8.7 nM .
    MK-7845
  • HY-134761

    c-Myc Cancer
    EN4 is a covalent ligand that targets cysteine 171 (C171) of MYC. EN4 is selective for c-MYC over N-MYC and L-MYC. EN4 inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis .
    EN4
  • HY-151758

    ADC Linker Others
    Methyltetrazine-PEG12-NHS ester is a click chemistry reagent containing an azide group. Methyltetrazine-PEG12-NHS ester reacts with compounds containing TCO to form stable covalent bonds .
    Methyltetrazine-PEG12-NHS ester
  • HY-147250A

    RLY-4008 hydrochloride

    FGFR Cancer
    Lirafugratinib (RLY-4008) hydrochloride is an orally active, irreversible and highly selective FGFR2 inhibitor with an IC50 of 3 nM. Lirafugratinib hydrochloride covalently binds to Cys491. Lirafugratinib hydrochloride targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs .
    Lirafugratinib hydrochloride
  • HY-147250

    RLY-4008

    FGFR Cancer
    Lirafugratinib (RLY-4008) is an orally active, irreversible and highly selective FGFR2 inhibitor with an IC50 of 3 nM. Lirafugratinib covalently binds to Cys491. Lirafugratinib targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs .
    Lirafugratinib
  • HY-156395

    Others Cancer
    MN551 is a potent inhibitor of cysteine-directed electrophilic covalent that plays important roles in the biology of SOCS2 and its CRL5 complex, and as E3 ligase handles in proteolysis targeting chimera (PROTACs) to induce targeted protein degradation .
    MN551
  • HY-163327

    Others Neurological Disease
    pFBC ([ 18F]pEBC) is a covalent CLIP-tag radiotracer for detection of viral reporter gene transfer in the murine brain. pFBC can be used in neurobiological research .
    pFBC
  • HY-143903

    PIN1 Cancer
    ZL-Pin13 is a high potent cell-active covalent inhibitor targeting the Pin1 (Peptidyl-Prolyl Isomerase NIMA-Interacting-1) with an IC50 of 67 nM. ZL-Pin13 effectively inhibits the proliferation and downregulated the Pin1 substrates in MDA-MB-231 cells .
    ZL-Pin13
  • HY-156007

    SARS-CoV Virus Protease Infection
    SARS-CoV-2 3CLpro-IN-21 (Compound D6) irreversibly and covalently inhibits SARS-CoV-2 3CL pro with an IC50 of 0.03 μM. SARS-CoV-2 3CLpro-IN-21 also inhibits SARS-CoV-13CL pro with an IC50 of 0.12μM .
    SARS-CoV-2 3CLpro-IN-21
  • HY-152108

    SARS-CoV Infection
    SARS-CoV-2 Mpro-IN-6 is a covalent, irreversible and selective SARS-CoV-2 M pro inhibitor with an IC50 of 0.18 μM. SARS-CoV-2 Mpro-IN-6 does not inhibit human cathepsins B, F, K, and L, and caspase 3 .
    SARS-CoV-2 Mpro-IN-6
  • HY-W229874

    Others Cancer
    EN106 is a potent inhibitor of FEMIB. EN106 is a cysteine-reactive covalent ligand. EN106 disrupts recognition of the key reductive stress substrate of FEM1B, FNIP1 .
    EN106
  • HY-155981

    SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-18 (Compound 3C) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 0.478 μM). SARS-CoV-2 3CLpro-IN-18 inhibits SARS-CoV-2 in Vero E6 cells (EC50= 2.499 μM) with low cytotoxicity (CC50 > 200 μM) .
    SARS-CoV-2 3CLpro-IN-18
  • HY-12903
    Macozinone
    4 Publications Verification

    PBTZ169

    Bacterial Antibiotic Infection
    Macozinone (PBTZ169) is a bactericidal benzothiazinone and a potent DprE1 (decaprenylphosphoryl-β-d-ribose 2′-oxidase) inhibitor. Macozinone inhibits the essential flavoprotein DprE1 by forming a covalent bond with the active-site Cys387 residue. Macozinone has antituberculosis effect .
    Macozinone
  • HY-14645
    (-)-DHMEQ
    25+ Cited Publications

    Dehydroxymethylepoxyquinomicin

    NF-κB Inflammation/Immunology Cancer
    (-)-DHMEQ (Dehydroxymethylepoxyquinomicin) is a potent, selective and irreversible NF-κB inhibitor that covalently binds to a cysteine residue. (-)-DHMEQ inhibits nuclear translocation of NF-κB and shows anti-inflammatory and anticancer activity .
    (-)-DHMEQ
  • HY-119390

    DNA Methyltransferase Cancer
    AA-CW236 is a MGMT (O6-methylguanine DNA methyltransferase) inhibitor. AA-CW236 targets MGMT active site Cys145 for covalent modification .
    AA-CW236
  • HY-121539

    TRP Channel Neurological Disease
    Supercinnamaldehyde is a potent transient receptor potential ankyrin 1 (TRPA1) activator with an EC50 value of 0.8 μM. Supercinnamaldehyde activates TRPA1 ion channels through covalent modification of cysteines .
    Supercinnamaldehyde
  • HY-150927

    Ras Cancer
    G12Si-2, an analog of G12Si-1 (HY-150926), is a negative control tool. G12Si-2 is not a covalent inhibitor of the G12S mutant of K-Ras .
    G12Si-2
  • HY-131704

    FGFR Cancer
    FGFR4-IN-5 is a potent and selective covalent FGFR4 inhibitor with an IC50 of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma research .
    FGFR4-IN-5
  • HY-144733

    Estrogen Receptor/ERR Apoptosis Cancer
    ERα antagonist 1 (Compound 19d) is a potent, selective, covalent estrogen receptor α (ERα) antagonist. ERα antagonist 1 induces apoptosis and cell cycle G0/G1 phase arrest in MCF-7 cells .
    ERα antagonist 1
  • HY-157144

    SARS-CoV Infection
    SARS-CoV-2-IN-68 (compound 6C) is a covalent SARS-CoV-2 PLpro/Mpro inhibitor with potent antiviral activities. SARS-CoV-2-IN-68 binds to Zn-finger domain of PLpro .
    SARS-CoV-2-IN-68
  • HY-130149
    Adagrasib
    15+ Cited Publications

    MRTX849

    Ras Cancer
    Adagrasib (MRTX849) is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity. Adagrasib covalently binds to KRAS G12C at the cysteine at residue 12, locks the protein in its inactive GDP-bound conformation, and inhibits KRAS-dependent signal transduction .
    Adagrasib
  • HY-47573

    G Protein-coupled Receptor Kinase (GRK) Cardiovascular Disease Cancer
    CCG273441 is a covalent inhibitor of G protein-coupled receptor (GPCR) kinase 5 (GRK5) with an IC50 value of 3.8 nM. CCG273441 is highly selective to GRK5 over GRK2 (IC50=4.8 μM) by binding Cys474, a GRK5 subfamily-specific residue, as a covalent handle .
    CCG273441
  • HY-161354

    JAK Apoptosis Inflammation/Immunology
    JAK3 covalent inhibitor-2 (compound J1b) is a selective, orally potent JAK3 inhibitor (IC50=7.2 nM) with low toxicity, anti-inflammatory activity and good bioavailability .
    JAK3 <em>covalent</em> inhibitor-2
  • HY-18930

    CDK Cancer
    NU6300 is a covalent, irreversible and ATP-competitive CDK2 inhibitor with an IC50 value of 0.16 μM. NU6300 can be used for the research of eukaryotic cell cycle- and transcription-related .
    NU6300
  • HY-19706
    ARS-853
    2 Publications Verification

    Ras Apoptosis Cancer
    ARS-853 is a cell-active, selective, covalent KRAS G12C inhibitor with an IC50 of 2.5 μM. ARS-853 inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation .
    ARS-853
  • HY-151523

    Ras Cancer
    KRas G12R inhibitor 1 (compound 3) is a KRas G12R selective covalent inhibitor that exploits the strong nucleophilicity of mutant cysteines and binds irreversibly in the Switch II region of K-Ras. KRas G12R inhibitor 1 can be used in cancer research .
    KRas G12R inhibitor 1
  • HY-144448

    FAK Apoptosis Cancer
    FAK-IN-2 is a potent and orally active focal adhesion kinase (FAK) inhibitor, with anticancer activity (FAK IC50= 35 nM). FAK-IN-2 covalently inhibits the autophosphorylation of FAK in a dose-dependent manner, and inhibits the clone formation and migration of tumor cells, inducing apoptosis .
    FAK-IN-2
  • HY-114436
    MRTX-1257
    3 Publications Verification

    Ras Cancer
    MRTX-1257 is a selective, irreversible, covalent and orally active KRAS G12C inhibitor, with an IC50 of 900 pM for KRAS dependent ERK phosphorylation in H358 cells .
    MRTX-1257
  • HY-143899

    Fungal Infection
    FBA-IN-1 (compound 2a11) is a first-in-class, covalent and allosteric inhibitor of fructose-1,6-bisphosphate aldolase from Candida albicans (CaFBA). FBA-IN-1 inhibits the growth of Azole-resistant strains 103 with the MIC80 of 1 μg/mL .
    FBA-IN-1
  • HY-D1372

    Fluorescent Dye Others
    Cyanine3 amine hydrochloride, an analog of Cyanine3 amine, is a potent green fluorescent dye. Cyanine3 amine hydrochloride has the primary amine group and is covalently coupled with reactive groups such as NHS esters, carboxy groups (after carbodiimide activation), and epoxides. (λex=555 nm, λem=570 nm) .
    Cyanine3 amine hydrochloride
  • HY-D1372A

    Fluorescent Dye Others
    Cyanine3 amine (TFA), an analog of Cyanine3 amine, is a potent green fluorescent dye. Cyanine3 amine (TFA) has the primary amine group and is covalently coupled with reactive groups such as NHS esters, carboxy groups (after carbodiimide activation), and epoxides. (λex=555 nm, λem=570 nm) .
    Cyanine3 amine TFA
  • HY-114352

    Fluorescent Dye Others
    BODIPY FL-X is a green-fluorescent dye. BODIPY FL-X has the succinimidyl ester covalently coupled to proteins. BODIPY FL-X has high fluorescence quantum yield and is relatively insensitive to pH change. (λex=504 nm, λem=510 nm) .
    BODIPY FL-X
  • HY-154854

    Histone Methyltransferase Cancer
    BBDDL2059 is a selective covalent inhibitor of histone methyltransferase EZH2 with an IC50 of 1.5 nM for EZH2-Y641F. BBDDL2059 inhibits lymphoma cell growth at nanomolar concentrations and can be used for anticancer research .
    BBDDL2059

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: